D
Deepti Aurora-Garg
Researcher at Merck & Co.
Publications - 28
Citations - 1997
Deepti Aurora-Garg is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Cancer. The author has an hindex of 13, co-authored 22 publications receiving 752 citations.
Papers
More filters
Journal ArticleDOI
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle,Marwan Fakih,Juanita Lopez,Manisha H. Shah,Ronnie Shapira-Frommer,Kazuhiko Nakagawa,Hyun Cheol Chung,Hedy L. Kindler,Jose A. Lopez-Martin,Wilson H. Miller,Antoine Italiano,Steven Kao,Sarina Anne Piha-Paul,Jean Pierre Delord,Robert R. McWilliams,David Fabrizio,Deepti Aurora-Garg,Lei Xu,F. Jin,Kevin Norwood,Yung-Jue Bang +20 more
TL;DR: The association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously treated, advanced solid tumours, was prospectively explored.
Journal ArticleDOI
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Luis Paz-Ares,Corey J. Langer,Silvia Novello,Balazs Halmos,Ying Cheng,Shirish M. Gadgeel,Rina Hui,S. Sugawara,Hossein Borghaei,Razvan Cristescu,Deepti Aurora-Garg,Andrew Albright,Andrey Loboda,J. Kobie,Jared Lunceford,M. Ayers,Gregory M. Lubiniecki,M.C. Pietanza,Bilal Piperdi,M.C. Garassino +19 more
TL;DR: Paz-Ares et al. as mentioned in this paper explored the relationship between tTMB and efficacy in KEYNOTE-021 C and G (nonsquamous; NCT02039674), 189 and NNNSCLC, and 407 (squamous), respectively, and found that TMB was not significantly associated with efficacy of pembro + chemo or of chemo alone as 1L therapy for metastatic NSCLC.
Journal ArticleDOI
Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
Roy S. Herbst,Gabriel Lima Lopes,Dariusz M. Kowalski,Makoto Nishio,Y-L. Wu,G. de Castro Junior,Paul Baas,Dong Wook Kim,Matthew A. Gubens,Razvan Cristescu,Deepti Aurora-Garg,Andrew Albright,M. Ayers,Andrey Loboda,Jared Lunceford,J. Kobie,Gregory M. Lubiniecki,M.C. Pietanza,Bilal Piperdi,Tony Mok +19 more
Journal ArticleDOI
Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
Aurélien Marabelle,Marwan Fakih,J. Lopez,Manisha H. Shah,Ronnie Shapira-Frommer,Kazuhiko Nakagawa,H.C. Chung,Hedy L. Kindler,Jose A. Lopez-Martin,Wilson H. Miller,Antoine Italiano,Steven Kao,Sarina Anne Piha-Paul,J.-P. Delord,Robert R. McWilliams,Deepti Aurora-Garg,Mei Chen,F. Jin,Kevin Norwood,Y-J. Bang +19 more
Journal ArticleDOI
OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
M.C. Garassino,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,G. Speranza,Martin Reck,Rina Hui,Michael Boyer,Razvan Cristescu,Deepti Aurora-Garg,Andrew Albright,Andrey Loboda,J. Kobie,Jared Lunceford,M. Ayers,Gregory M. Lubiniecki,Bilal Piperdi,M.C. Pietanza,Edward B. Garon +19 more